A detailed history of Macquarie Group LTD transactions in Uni Qure N.V. stock. As of the latest transaction made, Macquarie Group LTD holds 706,166 shares of QURE stock, worth $12.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
706,166
Previous 706,166 -0.0%
Holding current value
$12.3 Million
Previous $3.16 Million 10.05%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 21, 2023

SELL
$18.12 - $27.32 $6,233 - $9,398
-344 Reduced 0.05%
706,166 $16 Million
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $10,714 - $16,115
-631 Reduced 0.09%
706,510 $13.3 Million
Q1 2021

May 14, 2021

SELL
$29.24 - $42.03 $8,742 - $12,566
-299 Reduced 0.04%
707,141 $23.8 Million
Q2 2020

Aug 11, 2020

BUY
$45.06 - $67.74 $442,624 - $665,410
9,823 Added 1.41%
707,440 $31.9 Million
Q4 2019

Feb 14, 2020

BUY
$37.13 - $74.62 $60,039 - $120,660
1,617 Added 0.23%
697,617 $50 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $118,080 - $230,400
3,000 Added 0.43%
696,000 $27.4 Million
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $685,880 - $1.07 Million
13,000 Added 1.91%
693,000 $54.2 Million
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $2.27 Million - $5.68 Million
83,000 Added 13.9%
680,000 $40.6 Million
Q3 2018

Nov 15, 2018

SELL
$29.75 - $43.08 $56,525 - $81,852
-1,900 Reduced 0.32%
597,000 $21.7 Million
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $195,444 - $355,466
8,900 Added 1.51%
598,900 $22.6 Million
Q1 2018

May 11, 2018

BUY
$17.1 - $26.61 $990,962 - $1.54 Million
57,951 Added 10.89%
590,000 $13.9 Million
Q4 2017

Feb 15, 2018

BUY
$9.47 - $19.59 $4.38 Million - $9.05 Million
462,049 Added 660.07%
532,049 $10.4 Million
Q3 2017

Nov 08, 2017

BUY
$7.7 - $9.6 $539,000 - $672,000
70,000
70,000 $672,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.